Shanghai HeartCare Medical Technology Corporation (6609) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.6B
Fair value as of: Jul 7, 2026
From 24 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from HK$55.20 to HK$43.12 (−21.9%) since Jul 2, 2026. Share price +20.0% over the past month.
A strong business, but screening 15% overvalued on our models.
What matters now
- A high-quality business (quality 85/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- Our model range runs from HK$32.34 (bear) to HK$53.90 (bull), base HK$43.12. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 85/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range HK$12.32 – HK$145.80 · fair‑value band HK$32.34 – HK$53.90 · the HK$50.80 price screens above the HK$43.12 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Shanghai HeartCare Medical Technology Corporation (6609) currently trades at HK$50.80, while our model-based Fair Value estimate is HK$43.12, implying the stock looks roughly 15.1% overvalued today. The Quality Score stands at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai HeartCare Medical Technology Corporation generated revenue of HK$408M at a net margin of 20.4%. Revenue grew 49.1% year over year. It earns a return on equity of 7.6%. The balance sheet holds a net cash position of HK$547M. Fundamentals as of Jul 7, 2026
Our scenario range runs from HK$32.34 (bear case) to HK$53.90 (bull case); at HK$50.80, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -15%, 6609 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (HK$130.62) versus Asset-Based (HK$25.61). Highest evidence: Growth DCF (72).
Notify me when 6609 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 84 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices in Mainland China.
Full company description
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices in Mainland China. The company offers thrombectomy stent, aspiration pump, and aspiration catheter products for the treatment of acute ischemic stroke; and intracranial drug-eluting stent, intracranial balloon dilatation catheter, intracranial low pressure balloon dilatation catheter, carotid artery balloon dilatation catheter, embolization protection system, and carotid artery stent products for the treatment of neurovascular stenosis. It also provides embolic coil, intracranial stent, neurovascular occlusion balloon system, and flow diverter devices for the treatment of hemorrhagic stroke; left atrial appendage occluder for the prevention of ischemic stroke; and peripheral interventional devices, including fibered occlusion coil, disposable venous ablation catheter, and peripheral thrombus AP catheter. In addition, the company provides neuro-interventional access devices, such as balloon guiding catheter, distal access catheter, microcatheter, microcatheter for coiling, microcatheter for flow diverter device, navigation catheter, vascular closure device, neuro-interventional micro, guidewire, support catheter, neuro-interventional microcatheter, radial access, catheter system, and neuro balloon delivery catheter; thrombectomy stent for the treatment of acute ischemic stroke; embolic coil for the treatment of hemorrhagic stroke. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai HeartCare Medical Technology Corporation reported revenue of HK$408M in FY2025 versus HK$90.1M in FY2021, a compound +45.9%/yr. Reported net income was HK$83.3M in FY2025.
6609 screens 15% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Shanghai HeartCare Medical Technology Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai HeartCare Medical Technology Corporation (6609) overvalued or undervalued?
What is the fair value of 6609?
What is the quality score of 6609?
What is the revenue of Shanghai HeartCare Medical Technology Corporation (6609)?
What is the net profit margin of 6609?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai HeartCare Medical Technology Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.